Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products

Journal Title: IOSR Journal of Pharmacy (IOSRPHR) - Year 2014, Vol 4, Issue 2

Abstract

  Regulatory authorities are faced with different kinds of challenges when dealing with biosimilar products compared to other conventional generics. This is one of the reasons which made the FDA in the U.S. to delay authorizing biosimilars which have been in existence in Europe since 2005. Legal and scientific issues were sorted out in 2007 thus allowing the U.S. to approve Omnitrope and Valtropin. The BPCI Act was signed into law in 2009 and it was responsible for creating biological drug approval. Other important components of biosimilars are data exclusivity and patents whose aim are to preserve knowledge and innovation. They recognizes that an originator invest a lot of time and resources before producing a product. This document ends by discussing the challenges and opportunities of producing biosimilar products, and the issues to be considered before developing a biosimilar product.

Authors and Affiliations

Samrat Sisodia

Keywords

Related Articles

 Clinical Evaluation of 99mTc-MDP Three Phase Bone Scan and 99m Tc-UBI 29-41 Scintigraphy Imaging in Preferentially Detection Infection from Sterile Inflammation among Diabetic Patients with Suspected Foot Infection

 ABSTRACT : Ubiquicidin 29-41 (UBI 29-41) is an antimicrobial peptide with six positively charged residueswhich preferentially binds to the negatively charged groups present on the microbial membrane by electrostati...

Chemical-biological analysis of the barks of Anacardium occidentale Linn and Psidium guajava Linn

The use of medicinal plants is a very common practice. Anacardium occidentale L. and Psidium guajava L. are widely used because of their antidiarrheal properties. This study aimed to perform phytochemical analyses and to...

Extraction and screening of bioactive compounds of some common hydrophyticand wetland plants from East Singbhum,Jharkhand, India.

Abstract:Five commonly available hydrophytic and wetland plants of East Singbhum, Jharkhand, Indiawere assessed for its bioactive compounds namely alkaloids, carbohydrate, glycoside, flavonoids, phenols, amino acids and...

 Potency of Nanopropolis Stinglessbee Trigona spp Indonesia as Antibacterial Agent

 Propolis is one of the natural produced by honey bee which have many benefits, due to its properties as antibacterial, antivirus, and anticancer. The aim of this study is to determine potency of nanopropolis ho...

 OSA: An awaking disorder!

 OSA is characterized by repeated narrowing or collapse of the upper airway during sleep. It is the most common sleep disordered breathing seen among general population and contributes to increased morbidity and mor...

Download PDF file
  • EP ID EP115645
  • DOI -
  • Views 126
  • Downloads 0

How To Cite

Samrat Sisodia (2014).  Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products. IOSR Journal of Pharmacy (IOSRPHR), 4(2), 24-26. https://europub.co.uk/articles/-A-115645